Indena’s bilberry extract may help to fight dry eye conditions, says study
08 Sep 2017 --- Indena has reported that its Mirtoselect bilberry extract may have an important role in “preserving adequate aqueous levels” in people possibly experiencing dry eye conditions. This is according to a new randomized, double-blind, placebo-controlled clinical study published in the European Review for Medical and Pharmacological Sciences.
“Mirtoselect through the beneficial effect on vascular circulation can improve oxygen and blood delivery to the eye restoring the functionality of tear secretion,” Antonella Riva, Product Research Manager at Indena, tells NutritionInsight. “Furthermore, the free radical scavenging properties counteract one of the major risk factors of DED, the oxidative stress.”
“It shows consistent health clinical benefits especially for eye health,” Riva adds. “This consistency is due to a deep attention to biomass collection, storage and reproducible batch-to-batch industrial production and its unique composition. Clinical findings are also linked with an optimal tolerability profile.”
Study shows tear production benefits
The aim of the study was to investigate the ability of bilberry extract to maintain adequate tear levels and to confirm its antioxidant potential, Indena notes in its press release. A total of 21 healthy subjects experiencing dry eye were enrolled and randomly assigned to receive supplementation with Mirtoselect, the Indena proprietary standardized bilberry extract that is said to contain 36 percent anthocyanins. The supplementation was with two tablets corresponding to 160mg daily or placebo for four weeks.
The results of Schimer’s test – indicating the volume of tear secretion – before and after the four-week period showed significant improvements in the mean values for the right eye and both eyes as well as a beneficial tendency for the left eye in the supplemented group, Indena reports. In the placebo group, the mean values of Schimer’s test at the end of the treatment were not significant.
“Aged people or those exposed to certain stress conditions for the eye (i.e. dust or dry environment) may experience discomfort, visual disturbance, and tear film instability with potential impairment of the ocular surface,” comments Riva. “Mirtoselect is supported by a strong clinical literature, confirming its efficacy profile in the realm of vascular health and ophthalmology. This last study opens a new application for our bilberry extract in subjects with visual fatigue and a higher tendency of dry eye. The observed antioxidant potential is of a great importance due to the fact that a potential relationship between dry eye and relative oxygen species is reported.”
“The history of Indena Mirtoselect dates back to 1970 [and] our standardized bilberry extract is supported by more than 30 published clinical trials,” says Cosimo Palumbo, Indena Marketing Director. “This is one of the best examples of how Indena pioneers the development of botanical-derived dietary ingredients, confirming its expertise in innovation and quality. We are extremely proud that today Mirtoselect is the only bilberry extract (Vaccinium myrtillus) supported by clinical data on this specific eye condition.”
The study by Riva A. et al., “The effect of a natural, standardized bilberry extract (Mirtoselect) in dry eye: a randomized, double blinded, placebo controlled trial,” can be found in the European Review for Medical and Pharmacological Sciences.
“The major applications investigated so far for Mirtoselect are in the realms of vascular health and ophthalmology (eye protection at the retina level), but epidemiological surveys, animal models and pilot clinical studies suggest a broader clinical profile of anthocyanins encompassing memory improvement, gastrointestinal and cardiovascular health,” Palumbo tells NutritionInsight of possible future commercial applications of Mirtoselect. “In particular, preliminary trials have shown potential metabolic syndrome and glucose metabolism management activity with the use of Mirtoselect (Hoggard N.), which may represent an opportunity as future application further to the continuing research in the eye health field of use.”
Asked about any further studies to investigate Mirtoselect’s benefits, Riva adds: “We have just completed a new clinical trial in retinopathies showing a good improvement of the electrophysiological response of the nervous system to visual stimuli in the responsive subjects.”
By Paul Creasy
